Academic Journal
Fabrication and In Vivo Evaluation of In Situ pH-Sensitive Hydrogel of Sonidegib–Invasomes via Intratumoral Delivery for Basal Cell Skin Cancer Management
العنوان: | Fabrication and In Vivo Evaluation of In Situ pH-Sensitive Hydrogel of Sonidegib–Invasomes via Intratumoral Delivery for Basal Cell Skin Cancer Management |
---|---|
المؤلفون: | Maha M. Ghalwash, Amr Gamal Fouad, Nada H. Mohammed, Marwa M. Nagib, Sherif Faysal Abdelfattah Khalil, Amany Belal, Samar F. Miski, Nisreen Khalid Aref Albezrah, Amani Elsayed, Ahmed H. E. Hassan, Eun Joo Roh, Shaimaa El-Housiny |
المصدر: | Pharmaceuticals, Vol 18, Iss 1, p 31 (2024) |
بيانات النشر: | MDPI AG, 2024. |
سنة النشر: | 2024 |
المجموعة: | LCC:Medicine LCC:Pharmacy and materia medica |
مصطلحات موضوعية: | basal cell skin cancer, sonidegib, invasomes, chitosan, bioavailability, targeting, Medicine, Pharmacy and materia medica, RS1-441 |
الوصف: | Background/Objectives: Basal cell skin cancer (BCSC) develops when skin cells proliferate uncontrollably. Sonidegib (SDB) is a therapeutic option for the treatment of BCSC by inhibiting hedgehog signaling. The problems with SDB’s low solubility, poor bioavailability, resistance, poor targeting, and first-pass action make it less effective when taken orally. This investigation set out to design an intratumoral in situ pH-sensitive hydrogel of SDB-invasomes (IPHS-INV) that can effectively treat BCSC by improving SDB’s bioavailability, sustainability, targeting, and efficacy while also reducing its resistance and undesirable side effects. Methods: Numerous S-INV formulations were developed using Box–Behnken Design Expert and tested before settling on the optimum S-INV formulation. An experimental 7, 12-dimethylbenzanthracene (DMBA) carcinoma rat model was used for in vivo studies of the IPHS-INV formulation after it was combined with chitosan. Results: Phospholipids (1.72% w/w), cholesterol (0.15% w/w), ethanol (1% v/v), and cineole (1.5% v/v) were shown to be the optimal components in the SDB-invasome formulation. The IPHS-INV formulation outperformed the permeation and bioavailability of free SDB by 7.14 and 6 times, respectively, and sustained its release by 57.41%. The IPHS-INV formulation showed a decrease in tumor volume of 99.05% and a reduction of hypercellular tumors, indicating its anti-cancer activity. The intratumoral IPHS-INV formulation maintained a higher concentration of SDB in tumors, indicating its targeting activity. Conclusions: These findings support the use of the intratumoral IPHS-INV formulation as an effective strategy for the treatment of BCSC. |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 1424-8247 |
Relation: | https://www.mdpi.com/1424-8247/18/1/31; https://doaj.org/toc/1424-8247 |
DOI: | 10.3390/ph18010031 |
URL الوصول: | https://doaj.org/article/0f600069b17e45ebb5a48f52868f96f5 |
رقم الانضمام: | edsdoj.0f600069b17e45ebb5a48f52868f96f5 |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 14248247 |
---|---|
DOI: | 10.3390/ph18010031 |